{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T07:35:04Z","timestamp":1793086504629,"version":"4.5.0"},"reference-count":85,"publisher":"Informa UK Limited","issue":"9","license":[{"start":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:00:00Z","timestamp":1788307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Drug Metabolism &amp; Toxicology"],"published-print":{"date-parts":[[2026,9,2]]},"DOI":"10.1080\/17425255.2026.2729203","type":"journal-article","created":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T14:43:33Z","timestamp":1788878613000},"page":"705-719","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Pharmacokinetics of novel drugs for the treatment of diabetic nephropathy"],"prefix":"10.1080","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1976-6789","authenticated-orcid":false,"given":"Taraneh","family":"Mousavi","sequence":"first","affiliation":[{"name":"University of Maryland","place":["Baltimore, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9424-8514","authenticated-orcid":false,"given":"Fadia T.","family":"Shaya","sequence":"additional","affiliation":[{"name":"University of Maryland","place":["Baltimore, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1075-1284","authenticated-orcid":false,"given":"Kashif M.","family":"Munir","sequence":"additional","affiliation":[{"name":"University of Maryland","place":["Baltimore, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8923-5209","authenticated-orcid":false,"given":"Stephen N.","family":"Davis","sequence":"additional","affiliation":[{"name":"University of Maryland School of Medicine","place":["Baltimore, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,9,10]]},"reference":[{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.2337\/dci22-0027"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc26-S011"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gft462"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.96931"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2025.1631053"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.95400"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-022-02223-0"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2025.2521086"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2022.06.008"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfae214"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfad183"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)30772-X"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1080\/14728214.2022.2155632"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/fcp.70037"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2642"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/sdi.12374"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12316"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13306"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12182"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2014.12.013"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.955"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12056"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/psp.2013.20"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1159\/000544936"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-014-0226-x"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics17121604"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1520268"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S506957"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2009.03536.x"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-017-0528-2"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-018-0649-2"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S470826"},{"key":"e_1_3_4_35_1","unstructured":"U.S. Food and Drug Administration. Dulaglutide: clinical pharmacology and biopharmaceutics review(s) [Internet]. 2014. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2014\/125469Orig1s000ClinPharmR.pdf"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-021-01012-2"},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.13099"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2007.02890.x"},{"key":"e_1_3_4_39_1","unstructured":"Therapeutic Goods Administration. Extract from the clinical evaluation report for lixisenatide [Internet]. 2012. Available from: https:\/\/www.tga.gov.au\/sites\/default\/files\/auspar-lixisenatide-130820-cer.pdf"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2025845"},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-023-01312-9"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13318-018-0483-9"},{"key":"e_1_3_4_43_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.263"},{"key":"e_1_3_4_44_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13318-019-00547-x"},{"key":"e_1_3_4_45_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.118.083337"},{"key":"e_1_3_4_46_1","unstructured":"European Medicines Agency. Finerenone EMA label [Internet]. 2022. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/kerendia-epar-public-assessment-report_en.pdf"},{"key":"e_1_3_4_47_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-021-01082-2"},{"key":"e_1_3_4_48_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-021-01083-1"},{"key":"e_1_3_4_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.metop.2023.100251"},{"key":"e_1_3_4_50_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.3362"},{"key":"e_1_3_4_51_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13315"},{"key":"e_1_3_4_52_1","unstructured":"U.S. Food and Drug Administration. Atrasentan USFDA label [Internet]. 2025. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/219208s000lbl.pdf"},{"key":"e_1_3_4_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2017.07.011"},{"key":"e_1_3_4_54_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14252"},{"key":"e_1_3_4_55_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2721"},{"key":"e_1_3_4_56_1","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6904-11-3"},{"key":"e_1_3_4_57_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-023-01306-7"},{"key":"e_1_3_4_58_1","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2024.2326025"},{"key":"e_1_3_4_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)02408-X"},{"key":"e_1_3_4_60_1","unstructured":"Clinicaltrials.gov. EASi-KIDNEYTM (the studies of heart & kidney protection with BI 690517 in combination with empagliflozin) [Internet]. 2026. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06531824"},{"key":"e_1_3_4_61_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfae263"},{"key":"e_1_3_4_62_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00210-025-03838-0"},{"key":"e_1_3_4_63_1","unstructured":"Clinicaltrials.gov. A phase III study to investigate the efficacy and safety of baxdrostat in combination with dapagliflozin on CKD progression in participants with CKD and high blood pressure. ClinicalTrials.gov ID NCT06268873 [Internet]. 2026. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06268873"},{"key":"e_1_3_4_64_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41440-022-01070-4"},{"key":"e_1_3_4_65_1","unstructured":"Mineralys Therapeutics Inc. Data for lorundrostat in chronic kidney disease and hypertension presented at American Society of Nephrology (ASN) kidney week 2025 [Internet]. 2025. Available from: https:\/\/ir.mineralystx.com\/news-events\/press-releases\/detail\/85\/data-for-lorundrostat-in-chronic-kidney-disease-and"},{"key":"e_1_3_4_66_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.70000"},{"key":"e_1_3_4_67_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.0000000000000418"},{"key":"e_1_3_4_68_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00210-024-03165-w"},{"key":"e_1_3_4_69_1","unstructured":"Clinicaltrials.gov. ZEUS - A research study to look at how ziltivekimab works compared to placebo in people with cardiovascular disease chronic kidney disease and inflammation (ZEUS) [Internet]. 2026. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05021835"},{"key":"e_1_3_4_70_1","doi-asserted-by":"publisher","DOI":"10.34067\/KID.0005862020"},{"key":"e_1_3_4_71_1","doi-asserted-by":"publisher","DOI":"10.34067\/KID.0000000000000447"},{"key":"e_1_3_4_72_1","doi-asserted-by":"publisher","DOI":"10.3238\/arztebl.2012.0546"},{"key":"e_1_3_4_73_1","doi-asserted-by":"publisher","DOI":"10.3390\/metabo13080897"},{"key":"e_1_3_4_74_1","unstructured":"U.S. Food and Drug Administration. Finerenone USFDA label [Internet]. 2025. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/215341s009lbl.pdf"},{"key":"e_1_3_4_75_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-013-0128-8"},{"key":"e_1_3_4_76_1","doi-asserted-by":"publisher","DOI":"10.1111\/nep.13839"},{"key":"e_1_3_4_77_1","unstructured":"U.S. Food and Drug Administration. Canagliflozin USFDA label [Internet]. 2023. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/204042s040lbl.pdf"},{"key":"e_1_3_4_78_1","doi-asserted-by":"publisher","DOI":"10.5414\/CP202157"},{"key":"e_1_3_4_79_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12024"},{"key":"e_1_3_4_80_1","volume-title":"StatPearls","author":"Padda IS","year":"2026","unstructured":"Padda IS, Mahtani AU, Parmar M. Sodium-glucose transport 2 (SGLT2) inhibitors. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 [last updated 2025 Sep 15; cited 2026 Apr 18]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK576405\/"},{"key":"e_1_3_4_81_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-023-01392-3"},{"key":"e_1_3_4_82_1","unstructured":"U.S. Food and Drug Administration. Semaglutide USFDA label [Internet]. 2024. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/213051s018lbl.pdf"},{"key":"e_1_3_4_83_1","doi-asserted-by":"publisher","DOI":"10.1080\/17425255.2021.1955856"},{"key":"e_1_3_4_84_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.2003.02007.x"},{"key":"e_1_3_4_85_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40495-025-00425-y"},{"key":"e_1_3_4_86_1","doi-asserted-by":"publisher","DOI":"10.1080\/17425255.2018.1440287"},{"key":"e_1_3_4_87_1","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.05150418"}],"container-title":["Expert Opinion on Drug Metabolism &amp; Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/17425255.2026.2729203","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/17425255.2026.2729203","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/17425255.2026.2729203","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T06:56:53Z","timestamp":1793084213000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/17425255.2026.2729203"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,2]]},"references-count":85,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9,2]]}},"alternative-id":["10.1080\/17425255.2026.2729203"],"URL":"https:\/\/doi.org\/10.1080\/17425255.2026.2729203","relation":{},"ISSN":["1742-5255","1744-7607"],"issn-type":[{"value":"1742-5255","type":"print"},{"value":"1744-7607","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,2]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iemt20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iemt20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2026-06-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-01","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-10","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}